Clinical trial
Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy…
NCT00099047 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00099047 |
|---|---|
| Title | Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy or Smoldering Myeloma |
| Official title | Biologic and Clinical Role of COX-2 Inhibitor (Celecoxib)in the Management of MGUS and Smoldering Myeloma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Smoldering Multiple Myeloma |
| Intervention type | Drug, Other |
| Interventions | celecoxib, placebo, laboratory biomarker analysis |
| Enrollment | 23 |
| Start date | Nov 1, 2004 |
| Primary completion | Jun 1, 2008 |
| Completion | Nov 1, 2008 |
| First posted | Dec 9, 2004 |
| Last update posted | Dec 30, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: